19.07.2011 • NewsJoseph JimenezNovartisQ2 2011

Novartis Posts Higher Q2 Profit

Novartis reported second-quarter net income of $2.73 billion or $1.13 per share versus $2.44 billion or $1.06 per share in the year-ago quarter.
Core net income for the quarter increased to $3.56 billion or $1.48 per share from $2 77 billion or $1.20 per share in the previous year.
Quarterly sales climbed to $14.92 billion from $11.72 billion in the prior year.

Analysts polled by Thomson Reuters expected the company to report earnings of $1.40 per share on revenues of $14.42 billion for the quarter. Analysts' estimates typically exclude special items.

Joseph Jimenez, chief executive officer of Novartis, commented, "We achieved strong sales growth of 19% in constant currencies and margin improvement of 0.4 percentage points in U.S. dollars. We further demonstrated the success of our R&D strategy with four major approvals and two filings in the second quarter. Our diversified healthcare portfolio, focused on high growth segments, is enabling us to generate superior results."

 

Company

Novartis Pharma GmbH

Roonstr. 25
90429 Nürnberg

Company contact







Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.